The phase 1 clinical trials evaluated escalating doses of CB-839 in patients with advanced solid tumors among the patients with triple-negative breast cancer, RCC, mesothelioma, NSCLC, fumarate hydratase (FH)-deficient tumors, succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) or non-GIST tumors, cMyc-mutated tumors, and isocitrate dehydrogenase-1 (IDH1)- or IDH2-mutant tumors in combination with standard of care chemotherapy
BPC-157: Continue 250-500 mcg twice daily Cryotherapy: Once daily post-activity application Introduce progressive loading appropriate to the injury type Monitor for signs of excessive inflammation (increased pain, swelling, heat) Chronic Condition Management Sustained approach for arthritis, chronic tendinopathy, or recurring injuries
Thats because glow isnt skin-deep
Alarmingly, over 90% of perimenopausal and postmenopausal females with OSAHS remain undiagnosed (8)
Certificates of Analysis (COA) and Material Safety Data Sheets (MSDS) are available upon request